Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with<sup>67</sup>Ga Scintigraphy

Front, Dov; Bar‐Shalom, Rachel; Mor, Maya; Haim, Nissim; Epelbaum, Ron; Frenkel, Alex; Gaitini, Diana; Kolodny, Gerald M.; Israel, Ora

doi:10.1148/radiology.214.1.r00ja03253

Cited by 72 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 The results concerning the usefulness of GS in determining the prognosis of patients with lymphoma were equivocal in recent studies. [20][21][22][23] The higher accuracy of FDG in HD, however, was confirmed by direct comparison of the two imaging modalities, 24 and in both HD and NHL a PETbased staging algorithm was found to be more cost-effective than conventional staging mainly based on GS, CT and MRI. 25 The question of prognosis is crucial for further treatment planning and follow-up strategies.…”

Section: Leukemiamentioning

confidence: 96%

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

et al. 2002

View full text Add to dashboard Cite

We have determined the predictive value of [ 18 F]2-fluoro-2-deoxy-glucose (FDG-PET) in patients with Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) scheduled for high-dose therapy with stem cell transplantation (HDT/SCT). Inclusion criteria were the presence of an FDG-PET scan after chemotherapy (ChT) within 8 weeks prior to HDT/SCT and available follow-up data. Sixteen patients (10 NHL and six HD) were observed during a follow-up period of 4 to 28 months (median 13 months). Before SCT, five patients had a negative PET, three were weakly positive, two moderately positive, and six strongly positive. None of the five patients with a negative PET before HDT/SCT relapsed and two of three patients with a weakly positive scan are still in remission after HDT/SCT. Of eight patients with a moderate or high positive PET before HDT/SCT, seven relapsed and one died of early HDT/SCT related complications (P Ͻ 0.01). Three of eight relapsing patients died of lymphoma 5 to 10 months after SCT and in one additional patient not responding to HDT/SCT, the main cause of death was chronic toxicity 4 months after transplantation. After 12 months, in PET-negative patients the overall and relapse-free survival was 100%, in PET-positive patients 55% and 18%, respectively. In NHL, two patients with negative PET, but with an age-adjusted international prognostic index (AaIPI) of 2 and one with AaIPI ‫؍‬ 1 are still in remission. In the seven PET-positive subjects, one patient with AaIPI = 0, three with AaIPI ‫؍‬ 1, and two with AaIPI ‫؍‬ 2 relapsed. We conclude that FDG-PET is accurate in the prediction of relapse prior to HDT/SCT in patients with lymphoma. It provides additional information when compared with the AaIPI.

show abstract

Section: Leukemiamentioning

confidence: 96%

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Whereas some authors [16,27] found no differences between these two groups of patients, others [23,28] have reported that patients transplanted with measurable disease at ASCT have a worse outcome. In this sense, 67 Ga scan has successfully been used for many years for this purpose in patients with lymphoma after standard chemotherapy [29][30].…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation

et al. 2008

View full text Add to dashboard Cite

(67)Ga scan helps to identify, in the pre-transplant evaluation, two groups with a different outcome: one group of patients with positive CT and negative (67)Ga scans pre-transplant, who showed a favorable outcome with a low rate of relapse, and the other group of patients with both positive CT and (67)Ga scans pre-transplant, who showed a poor prognosis and did not benefit from autologous stem-cell transplantation. They should have been offered other therapeutic strategies.

show abstract

“…Some authors have reported the usefulness of 67 Ga scintigraphy early after chemotherapy to predict prognosis in patients with nonHodgkin's lymphoma [14,15]. In this respect, 67 Ga SPET might be useful for predicting not only the future fate of the residual viable cell fraction but also patient prognosis.…”

Section: Future Implicationsmentioning

confidence: 99%

Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: a preliminary study

et al. 2002

View full text Add to dashboard Cite

About 20 years ago, gallium-67 planar scintigraphy was introduced for the evaluation of advanced esophageal squamous cell carcinoma (AESCC). Although single-photon emission tomography (SPET) is now available in many institutions, there have been no reports regarding the evaluation of AESCC using (67)Ga SPET. The aims of this preliminary study were to assess the potential of (67)Ga SPET for the detection of AESCC and to further evaluate whether (67)Ga SPET can predict the effect of preoperative chemoradiotherapy on AESCC. Thirty-eight patients with histologically proven AESCC (35 men and 3 women, mean age 62+/-6.9 years) underwent (67)Ga SPET before and after preoperative chemoradiotherapy. The histological response to the chemoradiotherapy was determined from a surgical specimen of the esophagus: grade 0, 100% viable tumor cells; grade 1a, 99%-67%; grade 1b, 66%-34%; grade 2, 33%-1%; grade 3, no viable cells. Thirty-seven out of 38 AESCCs (97.4%) were detected on pre-chemoradiotherapy SPET. In these 37 cancers, the tumor-to-lung ratio (TLRpre) was 3.5+/-2 (range 1.5-9.6). Post-chemoradiotherapy SPET exhibited positive results in 22 cancers, with a TLRpost of 1.8+/-0.4 (range 1.1-2.6). No patient exhibiting a pathologically complete response had a positive post-chemoradiotherapy SPET result, whereas 80% of patients with negative post-chemoradiotherapy SPET (12/15) results had residual tumor. The percent reduction rate was defined as (TLRpre-TLRpost)/TLRpre x100 and did not correlate with histological response grade ( P=0.5169 for Kruskal-Wallis test). These results suggest that (67)Ga SPET is a powerful tool for the detection of AESCC. However, (67)Ga SPET seems to be of little use in predicting the effects of preoperative chemoradiotherapy on AESCC. Further studies are warranted in order to further clarify the clinical usefulness of (67)Ga SPET in patients with AESCC.

show abstract

Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with⁶⁷Ga Scintigraphy

Cited by 72 publications

References 16 publications

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation

Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: a preliminary study

Contact Info

Product

Resources

About

Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with67Ga Scintigraphy

Cited by 72 publications

References 16 publications

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation

Detection and chemoradiotherapeutic evaluation of advanced esophageal squamous cell carcinoma using gallium-67 SPET: a preliminary study

Contact Info

Product

Resources

About

Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with⁶⁷Ga Scintigraphy